

29 April 2015

Buy
Unchanged


宽松渐进，改革可期

交通银行(3328 HK)

Market Data: Apr,28

Closing Price (HK\$)	8.01
Price Target (HK\$)	10.12
HSCEI	14,715
HSCCI	5,591
52-week High/Low (HK\$)	8.09/4.77
Market Cap (USD Mn)	75,901
Market Cap (HK\$ Mn)	588,161
Shares Outstanding (Mn)	74,263
Exchange Rate (RMB-HK\$)	1.27

Price Performance Chart:



Source: Bloomberg

Analyst

Vivian Xue A0230511110001
BBE746
xuehr@swsresearch.com

Related Reports

"BOCOM(3328HK)_ Reforming the future " Mar 27,2015

The company does not hold any equities or derivatives of the listed company mentioned in this report ("target"), but then we shall provide financial advisory services subject to the relevant laws and regulations. Any affiliates of the company may hold equities of the target, which may exceed 1 percent of issued shares subject to the relevant laws and regulations. The company may also provide investment banking services to the target. The Company fulfills its duty of disclosure within its sphere of knowledge. The clients may contact compliance@swsresearch.com for relevant disclosure materials or log into www.swsresearch.com under disclosure column for further information. The clients shall have a comprehensive understanding of the disclosure and disclaimer upon the last page.

Financial summary and valuation

	2013	2014	2015E	2016E	2017E
Net interest income (Rmbm)	130,658	139,218	145,369	155,929	167,715
YOY (%)	8.77	6.55	4.42	7.26	7.56
Net income (Rmbm)	62,295	65,855	67,127	70,974	76,787
YOY (%)	6.73	5.71	1.93	5.73	8.19
EPS (Rmb)	0.84	0.89	0.90	0.96	1.03
Diluted EPS (Rmb)	0.84	0.89	0.90	0.96	1.03
BVPS (Rmb)	5.65	6.63	7.27	7.95	8.70
ROAE (%)	15.58	14.44	13.01	12.56	12.42
NPL ratio (%)	1.05	1.25	1.43	1.58	1.71
CAR (%)	14.52	15.18	15.37	14.41	0.00
PE (x)	7.54	7.14	7.00	6.62	6.12
PB (x)	1.12	0.95	0.87	0.80	0.73

Note: Diluted EPS is calculated as if all outstanding convertible securities, such as convertible preferred shares, convertible debentures, stock options and warrants, were exercised.

业绩符合预期。 交行周二公布一季度业绩。季末生息资产余额同比增长 10%，净息差同比回落 4 个基点至 2.29%。净利息收入同比增速达到 8%，非利息收入同比增速达到 29%。一季度净利润达到 190 亿元，基本每股收益 0.26 元，同比增长 1.5%，符合我们的预期。公司核心一级资本充足率由去年末的 11.30% 降至 11.21%，资本充足率由 14.04% 降至 13.56%。

市场担忧过度。 在经济下滑背景下，公司不良率由 1.25% 增加至 1.30%，拨备覆盖率下滑 6 个百分点至 173%。目前 PB 折价和超额拨备隐含的不良率达到 2.2%，高于我们最悲观情景假设下 2.0% 的不良率，风险已完全反映在估值中。

国企改革日益清晰。 交行正在研究深化混合所有制改革及提升公司治理和风控的方案。可能的混合所有制改革包括但不限于：（1）事业部改革等经营体制改革；（2）管理层薪酬构成改革和管理层股权激励；（3）员工持股计划；（4）引进更多的民营资本和其他非国有资本。如果改革方案最终获批且得到有效的执行，那么交行中长期核心竞争力有望实现显著提升。去年两轮管理层主动用自有资金增持股票并自愿锁定三年也显示了其对公司经营前景和估值提升的信心，更重要的是，使得管理层更有动力改善公司治理和经营业绩。

新一轮宽松渐进。 根据近期新闻报道，中国政府正考虑新一轮宽松政策，可能的措施包括向政策性银行注资以购买地方政府债券，或者向商业银行投放抵押补充贷款以增加银行投放基建贷款的积极性等。我们认为这些可能的政策反映了政府稳增长的决心，有利于改善市场对经济前景的预期，促进银行进一步的估值修复。

重申买入评级。 我们维持 2015 年和 2016 年 EPS 至 0.90 元和 0.96 元，对应 1.9% 和 5.7% 的同比增速。目前公司股价对应 0.87 倍 2015 年 PB，低于行业 1.07 倍的平均估值水平。鉴于市场情绪的回暖和行业估值中枢的提升，我们上调公司 2015 年目标 PB 至 1.2 倍，上调目标价至 10.12 港币，对应 26% 的上行空间，重申买入评级。

Investment highlights :

Results in line. Bank of Communications reported total interest earning assets in 1Q15 grew 10% YoY and net interest margin declined by 4bps YoY to 2.29%, driving net interest income up 8% YoY. Fees and commission income grew 29% YoY due to booming wealth management business. Net profit arrived at Rmb19bn and basic EPS reached Rmb0.26, representing 1.5% YoY, in line with our expectation. The bank's core tier-one capital adequacy ratio and overall CAR decreased from 11.30% and 14.04% at end-2014 to 11.21% and 13.56% by end-1Q15.

Concerns are overdone. Amid decelerating economic growth, Bocom's nonperforming loan ratio increased to 1.30%, up 0.05ppts from end-2014. The company's coverage ratio decreased to 173% (-6ppts vs end-2014). Its NPL ratio under our worst scenario may reach 2.0%, while the NPL ratio implied by the company's PB discount and extra provisions reached 2.2%. So we believe market concerns are overdone.

SOE reform visibility. The company is conducting a feasibility study into ownership reform. We believe BOCOM may be the first choice for the government in rolling out its reform of state-owned enterprises to the banking sector. Reforms may include management stock incentive and a broader employee stock ownership program. We expect such reforms would help the company improve its competitiveness in the mid-long term. Two rounds of management share purchases using their own funds and subject to a lock-up period of three years also underscore management's confidence in the company.

Possible quantitative easing ahead. It is reported that the Chinese government is considering a new round of quantitative easing, which may involve injecting capital to policy banks to finance the local government debt substitution plan or financing the expediting infrastructure investment via pledged supplementary lending towards commercial banks. These signals of government's intention to stimulate the economy will enhance market confidence in economic outlook. This would support further valuation recovery in the banking sector.

Maintain BUY. We maintain our EPS forecasts at Rmb0.90 in 15E (+1.9% YoY) and Rmb0.96 in 16E (+5.7% YoY). Currently BOCOM is trading at 0.87x 15E PB (vs sector average of 1.07x). Its H share is trading at 11% discount to A peer. In light of the easing expectation and booming market sentiment, we revise our target valuation to 1.1x 15E PB and revise up our target price from HK\$8.28 to HK\$10.12. With 26% upside, we maintain BUY recommendation.

Figure 1: Valuation table

Company	Code	Rating	Target price (HK\$)	Trading PE			Trading PB		
				13A	14A	15E	13A	14A	15E
CRCB	3618 HK	BUY	5.74	8.52	7.48	6.76	1.41	1.19	1.05
BOCOM	3328 HK	BUY	10.12	7.64	7.23	7.09	1.13	0.97	0.88
CMBC	1988 HK	O-PF	12.72	6.18	7.04	6.86	1.32	1.31	1.10
BOC	3988 HK	O-PF	5.23	7.91	7.31	7.15	1.34	1.19	1.08
ABC	1288 HK	O-PF	4.19	7.05	6.53	6.37	1.39	1.17	1.04
ICBC	1398 HK	Neutral	5.12	7.40	6.95	6.59	1.52	1.33	1.17
CCB	939 HK	Neutral	5.6	7.23	6.72	6.32	1.46	1.21	1.07
CITIC	998 HK	U-PF	5.53	6.89	6.63	6.62	1.20	1.03	0.91
CMB	3968 HK	U-PF	25.09	8.37	8.55	7.69	1.83	1.49	1.29

Source: Company data, SWS Research

APPENDIX

Figure 1: Forecast Income Statement

Rmbm	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015(E)	2016(E)	2017(E)
Interest Income	49,680	64,543	90,319	117,106	116,743	141,905	190,872	240,596	259,292	292,160	312,004	345,317	373,590
Interest expense	(18,089)	(24,740)	(36,175)	(51,244)	(50,075)	(56,910)	(88,271)	(120,470)	(128,634)	(152,942)	(166,635)	(189,388)	(205,875)
Net interest income	31,591	39,803	54,144	65,862	66,668	84,995	102,601	120,126	130,658	139,218	145,369	155,929	167,715
Fee and commission income	2,544	3,594	8,245	10,121	13,414	17,076	22,464	24,126	29,405	34,217	40,033	44,838	50,218
Fee and commission expense	(435)	(603)	(1,150)	(1,284)	(2,015)	(2,597)	(2,915)	(3,244)	(3,437)	(5,132)	(6,005)	(6,726)	(7,533)
Net fee and commission income	2,109	2,991	7,095	8,837	11,399	14,479	19,549	20,882	25,968	29,084	34,028	38,112	42,685
Other operating income	1,453	1,044	1,550	2,577	3,511	4,670	5,152	7,176	8,402	5,000	5,000	5,001	5,002
Operating income	35,153	43,838	62,789	77,276	81,578	104,144	127,302	148,184	165,028	173,303	184,397	199,042	215,403
Operating expense	(15,903)	(18,340)	(21,631)	(25,944)	(26,848)	(35,513)	(40,433)	(49,501)	(57,812)	(62,439)	(65,461)	(70,660)	(76,468)
Business tax and surcharges	(2,109)	(2,555)	(3,664)	(4,923)	(5,174)	(6,431)	(8,939)	(8,939)	(8,939)	(9,970)	(10,742)	(11,855)	(12,864)
Operating profit before provisions	17,141	22,943	37,494	46,409	49,556	62,200	77,930	89,744	98,277	100,893	108,194	116,527	126,070
Provision for impairment losses	(4,298)	(5,538)	(6,380)	(10,690)	(11,255)	(12,246)	(12,479)	(14,537)	(18,410)	(16,335)	(22,005)	(25,407)	(27,496)
Share of profits of an associate	-	-	-	-	-	-	-	4	42				
Profit before tax	12,843	17,405	31,114	35,719	38,301	49,954	65,451	75,211	79,909	84,558	86,188	91,121	98,574
Income tax	(3,600)	(5,136)	(10,712)	(7,229)	(8,047)	(10,782)	(14,634)	(16,739)	(17,448)	(18,603)	(18,961)	(20,047)	(21,686)
Minority interest	(6)	(5)	128	97	136	130	82	103	166	100	100	100	101
Net profit attributable to equity holders of the bank	9,249	12,274	20,274	28,393	30,118	39,042	50,735	58,369	62,295	65,855	67,127	70,974	76,787

Source : Company data, SWS Research

Figure2: Forecast Balance Sheet

Rmbm	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015(E)	2016(E)	2017(E)
Assets													
Cash and Balance with central bank	140,309	253,941	261,433	362,180	434,996	586,554	736,999	816,846	896,556	959,315	1,026,467	1,118,849	1,219,545
Cash/balances/Placements with banks and other financial institutions	170,101	118,623	156,110	331,511	222,671	262,976	443,240	520,963	566,429	829,990	892,082	984,432	1,086,948
Loans and advances to customers	758,773	910,307	1,085,724	1,298,776	1,801,538	2,190,490	2,505,385	2,879,628	3,193,063	3,416,577	3,655,738	3,984,754	4,343,382
Investments	317,571	400,868	565,541	627,727	775,235	809,184	805,829	886,081	1,085,248	1,161,215	1,242,500	1,329,475	1,422,539
Non interest-bearing assets	36,685	35,744	41,636	62,753	74,697	102,389	119,724	169,861	219,641	156,568	167,626	182,398	198,502
Total	1,423,439	1,719,483	2,110,444	2,682,947	3,309,137	3,951,593	4,611,177	5,273,379	5,960,937	6,523,665	6,984,413	7,599,909	8,270,916
Liabilities													
Deposits/Placements from banks and other financial institutions										291,048	311,422	428,427	466,986
Deposits from customers	84,094	236,107	332,556	569,453	653,172	717,032	854,499	942,989	1,126,563	1,304,733	1,396,883	1,519,982	1,654,183
Deposits from customers	1,220,839	1,352,890	1,567,142	1,865,815	2,372,055	2,867,847	3,283,232	3,728,412	4,157,833	4,448,881	4,760,303	5,188,730	5,655,716
Debts issued	12,292	12,292	38,207	40,000	53,000	52,000	81,803	79,572	106,857	106,857	106,857	106,857	106,857
Trading and Derivative liabilities	9,555	8,724	10,028	10,013	-	14,379	18,921	23,060	28,640	28,640	28,640	28,640	28,640
Non interest-bearing liabilities	13,513	18,975	29,190	47,571	66,485	76,678	99,934	117,899	119,560	140,259	150,165	163,398	177,825
Total	1,340,293	1,628,988	1,977,123	2,532,852	3,144,712	3,727,936	4,338,389	4,891,932	5,539,453	6,029,370	6,442,848	7,007,607	7,623,221
Shareholders' equity													
Share capital	45,804	45,804	48,994	48,994	48,994	56,260	61,886	74,263	74,263	74,263	74,263	74,263	74,263
Reserves	28,095	31,904	63,522	76,543	88,808	136,572	163,082	227,788	277,968	309,472	342,526	376,474	412,543
Retained Earnings	9,183	12,728	20,387	24,125	26,046	29,941	46,834	77,867	67,330	108,738	123,053	139,941	159,367
Total shareholders' equity	83,082	90,436	132,903	149,662	163,848	222,773	271,802	379,918	419,561	492,472	539,843	590,679	646,173
Minority Interests	64	59	418	433	577	884	986	1,529	1,923	1,823	1,723	1,623	1,522
Total shareholders' equity and liabilities	1,423,439	1,719,483	2,110,444	2,682,947	3,309,137	3,951,593	4,611,177	5,273,379	5,960,937	6,523,665	6,984,413	7,599,909	8,270,916

Source : Company data, SWS Research

Information Disclosure :

The views expressed in this report accurately reflect the personal views of the analyst. The analyst declares that neither he/she nor his/her associate serves as an officer of nor has any financial interests in relation to the listed corporation reviewed by the analyst. None of the listed corporations reviewed or any third party has provided or agreed to provide any compensation or other benefits in connection with this report to any of the analyst, the Company or the group company(ies). A group company(ies) of the Company confirm that they, whether individually or as a group (i) are not involved in any market making activities for any of the listed corporation reviewed; or (ii) do not have any individual employed by or associated with any group company(ies) of the Company serving as an officer of any of the listed corporation reviewed; or (iii) do not have any financial interest in relation to the listed corporation reviewed or (iv) do not, presently or within the last 12 months, have any investment banking relationship with the listed corporation reviewed.

Undertakings of the Analyst

I (We) am (are) conferred the Professional Quality of Securities Investment Consulting Industry by the Securities Association of China and have registered as the Securities Analyst. I hereby issue this report independently and objectively with due diligence, professional and prudent research methods and only legitimate information is used in this report. I am also responsible for the content and opinions of this report. I have never been, am not, and will not be compensated directly or indirectly in any form for the specific recommendations or opinions herein.

Disclosure with respect to the Company

The company is a subsidiary of Shenwan Hongyuan Securities. The company is a qualified securities investment consulting institute approved by China Securities Regulatory Commission with the code number ZX0065.

Releasing securities research reports is the basic form of the securities investment consulting services. The company may analyze the values or market trends of securities and related products or other relevant affecting factors, provide investment analysis advice on securities valuation/ investment rating, etc. by issuing securities research reports solely to its clients.

The Company fulfills its duty of disclosure within its sphere of knowledge. The clients may contact compliance@swsresearch.com for the relevant disclosure materials or log into www.swsresearch.com for the analysts' qualifications, the arrangement of the quiet period and the affiliates' shareholdings.

Introduction of Share Investment Rating

Security Investment Rating :

When measuring the difference between the markup of the security and that of the market's benchmark within six months after the release of this report, we define the terms as follows:

Trading BUY: Share price performance is expected to generate more than 20% upside over a 6-month period.

BUY: Share price performance is expected to generate more than 20% upside over a 12-month period.

Outperform: Share price performance is expected to generate between 10-20% upside over a 12-month period.

Hold: Share price performance is expected to generate between 10% downside to 10% upside over a 12-month period.

Underperform: Share price performance is expected to generate between 10-20% downside over a 12-month period.

SELL: Share price performance is expected to generate more than 20% downside over a 12-month period.

Industry Investment Rating:

When measuring the difference between the markup of the industry index and that of the market's benchmark within six months after the release of the report, we define the terms as follows:

Overweight : Industry performs better than that of the whole market ;

Equal weight : Industry performs about the same as that of the whole market ;

Underweight : Industry performs worse than that of the whole market.

We would like to remind you that different security research institutions adopt different rating terminologies and rating standards. We adopt the relative rating method to recommend the relative weightings of investment. The clients' decisions to buy or sell securities shall be based on their actual situation, such as their portfolio structures and other necessary factors. The clients shall read through the whole report so as to obtain the complete opinions and information and shall not rely solely on the investment ratings to reach a conclusion. The Company employs its own industry classification system. The industry classification is available at our sales personnel if you are interested.

HSCEI is the benchmark employed in this report.

Disclaimer :

This report is to be used solely by the clients of SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities, hereinafter referred to as the "Company"). The Company will not deem any other person as its client notwithstanding his receipt of this report.

This report is based on public information, however, the authenticity, accuracy or completeness of such information is not warranted by the Company. The materials, tools, opinions and speculations contained herein are for the clients' reference only, and are not to be regarded or deemed as an invitation for the sale or purchase of any security or other investment instruments.

The clients understand that the text message reminder and telephone recommendation are no more than a brief communication of the research opinions, which are subject to the complete report released on the Company's website (<http://www.swsresearch.com>). The clients may ask for follow-up explanations if they so wish.

The materials, opinions and estimates contained herein only reflect the judgment of the Company on the day this report is released. The prices, values and investment returns of the securities or investment instruments referred to herein may fluctuate. At different periods, the Company may release reports which are inconsistent with the materials, opinions and estimates contained herein.

Save and except as otherwise stipulated in this report, the contactor upon the first page of the report only acts as the liaison who shall not provide any consulting services.

The clients shall consider the Company's possible conflict of interests which may affect the objectivity of this report, and shall not base their investment decisions solely on this report. The clients should make investment decisions independently and solely at your own risk. Please be reminded that in any event, the company will not share gains or losses of any securities investment with the clients. Whether written or oral, any commitment to share gains or losses of securities investment is invalid. The investment and services referred to herein may not be suitable for certain clients and shall not constitute personal advice for individual clients. The Company does not ensure that this report fully takes into consideration of the particular investment objectives, financial situations or needs of individual clients. The Company strongly suggests the clients to consider themselves whether the opinions or suggestions herein are suitable for the clients' particular situations; and to consult an independent investment consultant if necessary.

Under no circumstances shall the information contained herein or the opinions expressed herein forms an investment recommendation to anyone. Under no circumstances shall the Company be held responsible for any loss caused by the use of any contents herein by anyone. Please be particularly cautious to the risks and exposures of the market via investment.

Independent investment consultant should be consulted before any investment decision is rendered based on this report or at any request of explanation for this report where the receiver of this report is not a client of the Company.

The Company possesses all copyrights of this report which shall be treated as non-public information. The Company reserves all rights related to this report. Unless otherwise indicated in writing, all the copyrights of all the materials herein belong to the Company. In the absence of any prior authorization by the Company in writing, no part of this report shall be copied, photocopied, replicated or redistributed to any other person in any form by any means, or be used in any other ways which will infringe upon the copyrights of the Company. All the trademarks, service marks and marks used herein are trademarks, service marks or marks of the Company, and no one shall have the right to use them at any circumstances without the prior consent of the Company.

This report may be translated into different languages. The Company does not warrant that the translations are free from errors or discrepancies.

This report is for distribution in Hong Kong only to persons who fall within the definition of professional investors whether under the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong) (the "SFO") or the Securities and Futures (Professional Investor) Rules (Chapter 571D of the laws of the Hong Kong under the SFO).

This report is for distribution in the United Kingdom only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) order 2001 (as amended) (the "Order") or (ii) are persons falling within Article 49(2)(a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc") of the Order (All such persons together being referred to as "Relevant Persons"). This document is directed only at Relevant Persons. Other Persons who are not Relevant Persons must not act or rely upon this document or any of its contents.

Disclaimer

This report was prepared, approved, published and distributed by the SWS Research Co., Ltd (subsidiary of Shenwan Hongyuan Securities) located outside of the United States (a "non-US Group Company"). This report is distributed in the U.S. by Enclave Capital LLC, a U.S. registered broker dealer, on behalf of SWS Research Co., Ltd only to major U.S. institutional investors (as defined in Rule 15a-6 under the U.S. Securities Exchange Act of 1934 (the "Exchange Act")) pursuant to the exemption in Rule 15a-6 and any transaction effected by a U.S. customer in the securities described in this report must be effected through Enclave Capital LLC (19 West 44th Street, suite 1700, New York, NY 10036).

Neither the report nor any analyst who prepared or approved the report is subject to U.S. legal requirements or the Financial Industry Regulatory Authority, Inc. ("FINRA") or other regulatory requirements pertaining to research reports or research analysts. No non-US Group Company is registered as a broker-dealer under the Exchange Act or is a member of the Financial Industry Regulatory Authority, Inc. or any other U.S. self-regulatory organization.

The information has been compiled or arrived from sources believed to be reliable and in good faith, but no representation or warranty, express or implied is made as to their accuracy, completeness or correctness. SWS Research Co., Ltd has not verified the factual accuracy, assumptions, calculations or completeness of the information. Accordingly, SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) accepts no liability whatsoever for any direct or consequential loss or damage arising from (i) the use of this communication (ii) reliance of any information contained herein, (iii) any error, omission or inaccuracy in any such Information or (iv) any action resulting there from. SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) provides the information for the purpose of the intended recipient's analysis and review. Accordingly you are advised to verify the factual accuracy, assumptions, calculations or completeness of the information.

Analyst Certification

Each of the analysts identified in this report certifies, with respect to the companies or securities that the individual analyses, that (1) the views expressed in this report reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this report.

Important US Regulatory Disclosures on Subject Companies

This material was produced by SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) solely for information purposes and for the use of the recipient. It is not to be reproduced under any circumstances and is not to be copied or made available to any person other than the recipient. It is distributed in the United States of America by Enclave Capital LLC and elsewhere in the world by SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or an authorized affiliate of SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities). This document does not constitute an offer of, or an invitation by or on behalf of SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or its affiliates or any other company to any person, to buy or sell any security. The information contained herein has been obtained from published information and other sources, which SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or its Affiliates consider to be reliable. None of SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) accepts any liability or responsibility whatsoever for the accuracy or completeness of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are made as of the date of this document. Emerging securities markets may be subject to risks significantly higher than more established markets. In particular, the political and economic environment, company practices and market prices and volumes may be subject to significant variations. The ability to assess such risks may also be limited due to significantly lower information quantity and quality. By accepting this document, you agree to be bound by all the foregoing provisions.

1. SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or its Affiliates have not recently been the beneficial owners of 1% or more of the securities mentioned in this report.
2. SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or its Affiliates have not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.
3. SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or its Affiliates have not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.
4. However, one or more person of SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or its affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon either on their own account or on behalf of their clients.
5. As of the publication of this report Enclave Capital LLC, does not make a market in the subject securities.
6. SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or its Affiliates may, to the extent permitted by law, act upon or use the above material or the conclusions stated above or the research or analysis on which they are based before the material is published to recipients and from time to time provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report

Distribution in Singapore

If distributed in Singapore, this report is meant only for Accredited Investors and Institutional Investors as defined under Section 4A of the Securities and Futures Act of Singapore. If you are not an Accredited Investor or an Institutional Investor, you shall ignore the report and its contents. The Singapore recipients of the report are to contact the Singapore office of Shenyin Wanguo Singapore Private Limited at 65-6323-5208, or 65-6323-5209 in respect of any matters arising from, or in connection with, the report.